Tumour microproteins could provide basis for cancer vaccines
A recent study published in Science Advances has identified a set of microproteins produced exclusively in liver tumours, which may provide a clear target for the development of a cancer vaccine.
A group of researchers from the Hospital del Mar Research Institute, Cima University of Navarra, and Pompeu Fabra University have discovered a group of microprotein molecules expressed exclusively in liver tumour cells. These microproteins may provide the basis for immune cell activation and targeting against the tumour, which could in turn be exploited to develop cancer vaccines.
Data from tumours and healthy tissue from over 100 liver cancer patients were integrated and allowed the researchers to identify the tumour microproteins. These microprotein molecules were coded by genes previously thought incapable of encoding proteins. Mar Alba, an ICREA researcher at the Hospital del Mar Research Institute, commented “In recent years, there has been increasing attention to this group of genes, which, due to their short length or low expression, were considered non-coding. New techniques have revealed that some of these genes can indeed produce small molecules.” These techniques include computational techniques like transcriptomics, proteomics, and translatomics. Laboratory experiments aimed at studying immune responses supplemented the studies.
The mechanism of cancer vaccines involves the immune system’s ability to recognise and target foreign cancer cells and the peptides they generate. However, low mutation rates in cancer cells have provided a challenge for the development of effective cancer vaccines. Microproteins, once believed too difficult to detect, can offer an alternative to researchers. “This study shows that there is a significant number of microproteins exclusively expressed in tumour cells that could be used to develop new treatments,” Marta Espinosa Camarena, a Hospital del Mar Research Institute researcher, stated.
Any potential cancer vaccine may also be used to treat many patients, as the same microproteins were expressed in several individuals. This differs from other potential cancer vaccine mechanisms that rely on patient-specific mutations. Puri Fortes, researcher at CIMA and CIBERehd, stated “We have seen that some of these microproteins can stimulate the immune system, potentially generating a response against cancer cells. This response can be enhanced with vaccines, similar to the coronavirus vaccines, but producing these microproteins. These vaccines could stop or reduce tumour growth.”
Future research hopes to further explore the application of these microproteins in developing and administering cancer vaccines.
Source:
Microproteins found in tumors could lead to cancer vaccines [Accessed July 15, 2024] https://www.eurekalert.org/news-releases/1050401
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance